Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7011270 | 0.79 | MAPT (0.62) | MAPTKDM4ENPSR1GLAALDH1A1 | |
| SCHEMBL21287698 | 0.79 | MAPT (0.55) | MAPTKDM4ENPSR1GLAALDH1A1 | |
| SCHEMBL10970382 | 0.77 | KDM4E (0.51) | MAPTKDM4ENPSR1GLAALDH1A1 | |
| SCHEMBL29952952 | 0.77 | MAPT (0.68) | MAPTKDM4ENPSR1GLAALDH1A1 | |
| SCHEMBL2218011 | 0.77 | THRB (0.62) | MAPTKDM4ENPSR1GLAALDH1A1 | |
| SCHEMBL23022393 | 0.76 | MAPT (0.55) | MAPTKDM4ENPSR1GLAALDH1A1 | |
| SCHEMBL10201502 | 0.76 | ELANE (0.52) | MAPTKDM4ENPSR1GLAALDH1A1 | |
| SCHEMBL29677209 | 0.76 | THRB (0.57) | MAPTKDM4ENPSR1GLAALDH1A1 | |
| SCHEMBL24697550 | 0.74 | KDM4E (0.56) | MAPTKDM4ENPSR1GLAALDH1A1 | |
| SCHEMBL5131549 | 0.72 | KDM4E (0.62) | MAPTKDM4ENPSR1GLAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2295442-A2 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2083014-A2 | Inhibitors of interleukin-1ß converting enzyme | Vertex Pharmceuticals Incorporated (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | BATCHELOR MARK J | 2008-02-14 | — | — | US | disclosed |
| US-20050143436-A1 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-30 | — | — | US | disclosed |
| US-20030225269-A1 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-04 | — | — | US | disclosed |
| US-6423840-B1 | FORMING N-ACYLAMINO COMPOUND | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-23 | — | — | US | disclosed |
| US-6258948-B1 | AN N-ACYLAMINO COMPOUND; ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INCORPORATED | 2001-07-10 | — | — | US | disclosed |
| US-6204261-B1 | Inhibitors of interleukin-1β Converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2001-03-20 | — | — | US | disclosed |
| EP-0869967-A2 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997022619-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | disclosed |
| US-5466701-A | Degenerative diseases | STERLING WINTHROP INC. (US) | 1995-11-14 | — | — | US | disclosed |
| US-5378720-A | Treatment of rheumatoid arthritis, emphysema, pancreatitis | STERLING WINTHROP INC. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0626378-A1 | Saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | MAPT 1662/4885KDM4E 3261/4885NPSR1 4495/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | MAPT 1662/4885KDM4E 3261/4885NPSR1 4495/4885 |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | MAPT 1774/4885KDM4E 3018/4885NPSR1 4486/4885 |
| US-20050143436-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | MAPT 1727/4885KDM4E 2997/4885NPSR1 4452/4885 |
| US-20030225269-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, APAF1, IL1B | MAPT 1841/4885KDM4E 2983/4885NPSR1 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.